Search Results

Your search for Rolf A. Stahel, MD matches 2 pages

Showing 1 - 2

By Rolf A. Stahel, MD / 2015 European Cancer Congress

Rolf A. Stahel, MD, on Results From the BELIEF Trial

Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology...

lung cancer

issues in oncology

By Matthew Stenger / Monday, August 18, 2014 3:03 PM

ALK-Positivity Prevalence on Immunohistochemistry and FISH in Resected Stage I to III Lung Adenocarcinoma

The European Thoracic Oncology Platform Lungscape ALK project is investigating the prevalence and prognostic impact of ALK-positivity in resected lung adenocarcinoma in a primarily European population. As reported in the Journal of Clinical Oncology by Blackhall and colleagues, the project has...

Apr

Today In Oncology

Search Results

Your search for Rolf A. Stahel, MD matches 2 pages

Rolf A. Stahel, MD, on Results From the BELIEF Trial

ALK-Positivity Prevalence on Immunohistochemistry and FISH in Resected Stage I to III Lung Adenocarcinoma

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being